BioPlus Co Ltd
KOSDAQ:099430
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (5.9), the stock would be worth ₩9 207.95 (58% upside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 3.7 | ₩5 840 |
0%
|
| 3-Year Average | 5.9 | ₩9 207.95 |
+58%
|
| 5-Year Average | 6.2 | ₩9 788 |
+68%
|
| Industry Average | 3.4 | ₩5 417.72 |
-7%
|
| Country Average | 1 | ₩1 649.49 |
-72%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
₩338.5B
|
/ |
Oct 2025
₩96.8B
|
= |
|
|
₩338.5B
|
/ |
Dec 2025
₩103.3B
|
= |
|
|
₩338.5B
|
/ |
Dec 2026
₩120.2B
|
= |
|
|
₩338.5B
|
/ |
Dec 2027
₩142.4B
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| KR |
B
|
BioPlus Co Ltd
KOSDAQ:099430
|
359.4B KRW | 3.7 | 22.4 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
58.8B USD | 0 | 0 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.7T JPY | 10.5 | 38.6 | |
| CH |
|
Alcon AG
SIX:ALC
|
29.2B CHF | 3.5 | 37.3 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
94.7B DKK | 3.4 | 23.5 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
13.5B USD | 3.4 | 33 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.3B GBP | 2.3 | 32.7 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.6B USD | 1.1 | -15.5 | |
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
890.2B JPY | 6.9 | 50.3 | |
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
36.7B CNY | 8.4 | 23.3 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8T KRW | 94.7 | -36.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.5 |
| Median | 1 |
| 70th Percentile | 2.4 |
| Max | 101 134.7 |
Other Multiples
BioPlus Co Ltd
Glance View
BioPlus Co., Ltd. is engaged in the manufacturing and supplying of diverse dermal fillers. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2021-09-27. The firm is engaged in the production and sale of biomaterials for tissue restoration used for temporary improvement of facial wrinkles, namely hyaluronic acid fillers. In addition, the Company is engaged in the production and sale of anti-adhesion agents that reduce the formation of adhesions in surgical areas, biomaterials for joint tissue repair, and other products.
